Ascent Solar Technologies Announces Closing of Up to $5.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

About this update from Aquarius Surgical Technologies Inc.

[{"type":"text","content":"Ascent Solar Technologies Announces Closing of Up to $5.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules$2 million upfront with up to approximately $3.5 million of potential aggregate proceeds upon the exercise in full of warrants\n\n\n\n THORNTON, Colo., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascent Solar Technologies, Inc. (NASDAQ: ASTI) (“Ascent” or the “Company”), today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 1,025,643 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 1,025,643 shares of common stock and short-term series B warrants to purchase up to 1,025,643 shares of common stock at a purchase price of $1.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and the short-term series B warrants have an exercise price of $1.70 and are exercisable immediately upon issuance. The series A warrants will expire five years from the effective date of the Resale Registration Statement (as defined below) and the short-term series B warrants will expire eighteen months from the effective date of the Resale Registration Statement.\n \n\n H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.\n \n\n The gross proceeds from the offering were approximately $2 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the series A warrants and the short-term series B warrants, if fully exercised on a cash basis, will be approximately $3.5 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants. The Company intends to use the net proceeds from the offering for general working capital needs.\n \n\n The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities ...

More updates from Aquarius Surgical Technologies Inc.